Inhibrx | Investors - News Releases

News Releases

Month Year

Month Year

Jan 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40
Sep 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

-INBRX-109 was well-tolerated; a maximum tolerated dose was not reached-
May 21, 2019

Inhibrx Announces $40M Investment from Viking Global Investors
Feb 19, 2019

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody
Jan 7, 2019

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies
Dec 6, 2018

Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
Oct 31, 2017

Inhibrx Wins CARB-X Award Of Up To $6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections
Sep 15, 2015

Inhibrx and The Alpha-1 Project Collaborate to Develop a Recombinant Alpha-1 Antitrypsin with Improved Properties

Inhibrx’s AAT-Fc therapeutic should benefit patients with enhanced efficacy and less frequent dosing
Jun 27, 2012

Inhibrx announces an Option & License Agreement with Celgene Corporation for Inhibrx Antibody Program

Show per page

Back To Top